Skip to main content

Tweets

CHECK: a prospective cohort study shows that Femoroacetabular impingement syndrome in is strongly associated with the development of radiographic hip OA (RHOA) within 10-yrs (OR 6.85 for incident RHOA and OR 47.82 for end-stage RHOA) https://t.co/Kt0bsIdpnS https://t.co/mSGRbQV4vI
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
TRUST: 10 Yr Japanese study of tacrolimus in 1355 SLE nephritis pts; half on TAC x 10yrs. TAC use assoc w/ signif reduction corticosteroid use (~16 mg/d @4wks to 7.2 mg/d @ 1Yr(P < 0.001). 9.7% w/ serious AEs. https://t.co/PsfCVZF4tk https://t.co/l3HkTRc4oC
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Elder adult Cohort study of 2413 women & 792 men w/ hip BMD-defined osteoporosis based on CT scans, shows 30% of women & 34% of men had hip Fx. Rx w/ alendronate (34%F; 24% M) signif lowered Fx rates (aOR 0.26 and 0.21, respectively) = no sex difference https://t.co/briuZAYVKx https://t.co/xrZ12TmMvM
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Literature review - Glucocorticoid use in elderly to be problematic. GC use may be assoc w/ remission, but GC increases AE rates, & there is difficulty w/ GC discontinuation. Goal: D/C GC early, but some may require for up to yrs to control Dz activity https://t.co/6liN0mubIv https://t.co/PiGKGSYrof
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
New Classification Criteria for Juvenile Axial Spondyloarthritis An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA). https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
In the UK, estimated cost of hardardous NSAID use is £31.43million (pounds) (£9.28m to £67.11m) over 10 yrs. High risk = Elderly >65y without gastroprotection, pts on anticoagulants; & Pts w/ heart failure, chronic kidney Dz , or Hx of peptic ulcer. https://t.co/bPXnQbQnNV https://t.co/aDLGHjLmhB
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Harris poll of 1286 #PsA pts (52% female) shows gender differences in perception. Women had different presenting Sxs, more joint tenderness, skin PSO, and enthesitis, and greater impact on well-being. Treating female PsA is different! https://t.co/H3PQkKCg9n https://t.co/FmwhgkVJ7J
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Polypharmacy Doubled in 20 Years. Polypharmacy (5+ Rx last month) went from 24% in 2000 to > 40% in 2020 https://t.co/2czI4DxlVm https://t.co/VAZkbxKrJP
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
FIRST registry of 1424 #RA pts found 732 achieving HAQ-DI <0.5 & 454 w/ pain VAS <4/10. Achieiing LDA in 1st 6mos predicted by seropositivity & JAKi use. Less likely were: older, failin ≥ 2 b/tsDMARDs, hi baseline HAQ& steroid use (not comorbidities) https://t.co/7y0uMV414j https://t.co/6aLPTzf5fm
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Location, Location, Location (7.26.2024) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Location matters; Geo-rheumatology? https://t.co/I81qpckOQG https://t.co/cyu64ThPkN
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Lg prospective (2013-2020) multinational, cohort of 3449 #SLE pts (F/U 2.8 yrs)- LLDAS (lupus low Dz activity achieved >= once in 73%. Sustained LLDAS >3mos assoc w/ signif less damage (HR 0·60), remission: (0·66) & flare (0·56). https://t.co/AFyOBWcIZf https://t.co/bHjmOuH7wN
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on RheumNow. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/PLnIOe9vuF to stay at the forefront of medical innovation. https://t.co/vXR12HprAp
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
×